Aisen, Paul S.

Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease

Benzinger, T. L. S., Blazey, T., Jack, C. R., Koeppe, R. A., Su, Y., Xiong, C., Raichle, M. E., Snyder, A. Z., Ances, B. M., Bateman, R. J., et al. (2013) · Proceedings of the National Academy of Sciences

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 391

A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease

Salloway, S., Farlow, M., McDade, E., Clifford, D. B., Wang, G., Llibre-Guerra, J. J., Hitchcock, J. M., Mills, S. L., Santacruz, A. M., Aschenbrenner, A. J., et al. (2021) · Nature Medicine

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 359

2014 Update of the Alzheimer’s Disease Neuroimaging Initiative: A review of papers published since its inception

Weiner, M. W., Veitch, D. P., Aisen, P. S., Beckett, L. A., Cairns, N. J., Cedarbaum, J., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., et al. (2015) · Alzheimer's & Dementia

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 348

Aducanumab: Appropriate Use Recommendations

Cummings, J., Aisen, P., Apostolova, L. G., Atri, A., Salloway, S., & Weiner, M. (2021) · The Journal of Prevention of Alzheimer's Disease

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 316

Tramiprosate in mild-to-moderate Alzheimer's disease — a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study)

Aisen, P. S., Gauthier, S., Ferris, S. H., Saumier, D., Haine, D., Garceau, D., Duong, A., Suhy, J., Oh, J., Lau, W. C., et al. (2011) · Archives of Medical Science

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 295

The AHEAD 3‐45 Study: Design of a prevention trial for Alzheimer's disease

Rafii, M. S., Sperling, R. A., Donohue, M. C., Zhou, J., Roberts, C., Irizarry, M. C., Dhadda, S., Sethuraman, G., Kramer, L. D., Swanson, C. J., et al. (2023) · Alzheimer's & Dementia

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 291

Females exhibit more extensive amyloid, but not tau, pathology in an Alzheimer transgenic model

Hirata-Fukae, C., Li, H.-F., Hoe, H.-S., Gray, A. J., Minami, S. S., Hamada, K., Niikura, T., Hua, F., Tsukagoshi-Nagai, H., Horikoshi-Sakuraba, Y., et al. (2008) · Brain Research

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 284

Aducanumab produced a clinically meaningful benefit in association with amyloid lowering

Cummings, J., Aisen, P., Lemere, C., Atri, A., Sabbagh, M., & Salloway, S. (2021) · Alzheimer's Research & Therapy

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 224

Machine learning for comprehensive forecasting of Alzheimer’s Disease progression

Fisher, C. K., Smith, A. M., Walsh, J. R., Diseases, C. A. M., Simon, A. J., Edgar, C., Jack, C. R., Holtzman, D., Russell, D., Hill, D., et al. (2019) · Scientific Reports

Dementia and Cognitive Impairment ResearchMachine Learning in Healthcare

Cited by 223

Adeno-Associated Viral Vector (Serotype 2)–Nerve Growth Factor for Patients With Alzheimer Disease: A Randomized Clinical Trial

Rafii, M. S., Tuszynski, M. H., Thomas, R. G., Barba, D., Brewer, J. B., Rissman, R. A., Siffert, J., Aisen, P. S., & for the AAV2-NGF Study Team (2018) · JAMA Neurology

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 219

Subregional neuroanatomical change as a biomarker for Alzheimer's disease

Holland, D., Brewer, J. B., Hagler, D. J., Fennema-Notestine, C., Dale, A. M., Initiative, T. A. D. N., Weiner, M., Thal, L., Petersen, R., Jack, C. R., et al. (2009) · Proceedings of the National Academy of Sciences

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 210

Genome-wide association study of CSF biomarkers Aβ 1-42 , t-tau, and p-tau 181p in the ADNI cohort

Kim, S., Swaminathan, S., Shen, L., Risacher, S. L., Nho, K., Foroud, T., Shaw, L. M., Trojanowski, J. Q., Potkin, S. G., Huentelman, M. J., et al. (2011) · Neurology

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 206

Preliminary Results of a Trial of Atabecestat in Preclinical Alzheimer’s Disease

Henley, D., Raghavan, N., Sperling, R., Aisen, P., Raman, R., & Romano, G. (2019) · New England Journal of Medicine

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 197

Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease

Vemuri, P., Wiste, H. J., Weigand, S. D., Knopman, D. S., Shaw, L. M., Trojanowski, J. Q., Aisen, P. S., Weiner, M., Petersen, R. C., Jack, C. R., et al. (2010) · Annals of Neurology

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 195

Cytokine Gene Expression as a Function of the Clinical Progression of Alzheimer Disease Dementia

Luterman, J. D., Haroutunian, V., Yemul, S., Ho, L., Purohit, D., Aisen, P. S., Mohs, R., & Pasinetti, G. M. (2000) · Archives of Neurology

Alzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration Mechanisms

Cited by 192

Using the Alzheimer’s Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer’s disease

Veitch, D. P., Weiner, M. W., Aisen, P. S., Beckett, L. A., DeCarli, C., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., Landau, S. M., et al. (2022) · Alzheimer's & Dementia

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 184

Amyloid-β 11 C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials

Liu, E., Schmidt, M. E., Margolin, R., Sperling, R., Koeppe, R., Mason, N. S., Klunk, W. E., Mathis, C. A., Salloway, S., Fox, N. C., et al. (2015) · Neurology

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 151

GWAS of longitudinal amyloid accumulation on18F-florbetapir PET in Alzheimer’s disease implicates microglial activation gene IL1RAP

Ramanan, V. K., Risacher, S. L., Nho, K., Kim, S., Shen, L., McDonald, B. C., Yoder, K. K., Hutchins, G. D., West, J. D., Tallman, E. F., et al. (2015) · Brain

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 133

Increasing participant diversity in AD research: plans for digital screening, blood testing, and a community-engaged approach in the Alzheimer’s Disease Neuroimaging Initiative 4

Weiner, M. W., Veitch, D. P., Miller, M. J., Aisen, P. S., Albala, B., Beckett, L. A., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., et al. (2023) · Alzheimer's & Dementia

Dementia and Cognitive Impairment ResearchEthics in Clinical Research

Cited by 126

Non-coding variability at the APOE locus contributes to the Alzheimer’s risk

Zhou, X., Chen, Y., Mok, K. Y., Kwok, T. C. Y., Mok, V. C. T., Guo, Q., Ip, F. C., Chen, Y., Mullapudi, N., Initiative, A. D. N., et al. (2019) · Nature Communications

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 120

The Alzheimer's Disease Neuroimaging Initiative in the era of Alzheimer's disease treatment: A review of ADNI studies from 2021 to 2022

Veitch, D. P., Weiner, M. W., Miller, M., Aisen, P. S., Ashford, M. A., Beckett, L. A., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., et al. (2024) · Alzheimer's & Dementia

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 113

The BIN1 rs744373 SNP is associated with increased tau-PET levels and impaired memory

Franzmeier, N., Rubinski, A., Neitzel, J., Ewers, M., (ADNI), T. A. D. N. I., Weiner, M. W., Aisen, P., Petersen, R., Jack, C. R., Jagust, W., et al. (2019) · Nature Communications

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 109

Identification of genetic risk factors in the Chinese population implicates a role of immune system in Alzheimer’s disease pathogenesis

Zhou, X., Chen, Y., Mok, K. Y., Zhao, Q., Chen, K., Chen, Y., Hardy, J., Li, Y., Fu, A. K. Y., Guo, Q., et al. (2018) · Proceedings of the National Academy of Sciences

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 96

Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer’s disease

Egan, M. F., Mukai, Y., Voss, T., Kost, J., Stone, J., Furtek, C., Mahoney, E., Cummings, J. L., Tariot, P. N., Aisen, P. S., et al. (2019) · Alzheimer's Research & Therapy

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 81